Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corporation demonstrates a positive outlook due to significant growth in its plasma segment, which achieved an impressive 18.6% organic growth rate, excluding CSL impacts, reflecting strong demand and market share gains. The company's gross margin increased by 380 basis points year-over-year, coupled with a 250 basis point increase in operating margin, highlighting improved operational efficiency and profitability. Additionally, Haemonetics is projecting free cash flow for FY26 between $170 million and $210 million, which represents an upward revision from previous estimates, further supporting a favorable financial outlook.

Haemonetics Corp reported a significant decline in plasma sales, reflecting a 10.1% organic decrease to $125.4 million, despite exceeding consensus expectations. The company has adjusted its financial guidance for FY2026, now forecasting a total reported revenue decline of 1% to 4%, along with a reduction in expected organic growth for the hospital segment from 8-11% to a more conservative 4-7%. Additionally, the overall slowdown in organic growth, shifting from a 0.5% increase in F1Q26 to a 1.8% decline in F2Q26, raises concerns about the company's future performance and competitive standing in the market.